MX2015005548A - Tratamiento de cancer con pomalidomida en un individuo con daño renal. - Google Patents
Tratamiento de cancer con pomalidomida en un individuo con daño renal.Info
- Publication number
- MX2015005548A MX2015005548A MX2015005548A MX2015005548A MX2015005548A MX 2015005548 A MX2015005548 A MX 2015005548A MX 2015005548 A MX2015005548 A MX 2015005548A MX 2015005548 A MX2015005548 A MX 2015005548A MX 2015005548 A MX2015005548 A MX 2015005548A
- Authority
- MX
- Mexico
- Prior art keywords
- pomalidomide
- cancer
- subject
- treatment
- impaired subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
En la presente se proporcionan los métodos para el tratamiento, prevención o manejo de uno o más síntomas de una enfermedad (p. ej., cáncer) en un individuo con daño renal, que consisten en administrar al individuo pomalidomida. También se proporcionan en la presente los métodos para el tratamiento, prevención o manejo de uno o más síntomas de una enfermedad (p. ej., cáncer) en un individuo con daño renal, que consisten en administrar al individuo una cantidad terapéutica eficaz de pomalidomida y dexametasona.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261722722P | 2012-11-05 | 2012-11-05 | |
US201361764466P | 2013-02-13 | 2013-02-13 | |
PCT/US2013/068237 WO2014071280A1 (en) | 2012-11-05 | 2013-11-04 | Treatment of cancer with pomalidomide in a renally impaired subject |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015005548A true MX2015005548A (es) | 2016-01-15 |
Family
ID=50628132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015005548A MX2015005548A (es) | 2012-11-05 | 2013-11-04 | Tratamiento de cancer con pomalidomida en un individuo con daño renal. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20150297579A1 (es) |
EP (1) | EP2914112A4 (es) |
JP (1) | JP2015535291A (es) |
CN (1) | CN104902754A (es) |
AU (1) | AU2013337352A1 (es) |
BR (1) | BR112015010039A2 (es) |
CA (1) | CA2889987A1 (es) |
EA (1) | EA201590883A1 (es) |
HK (1) | HK1214552A1 (es) |
IL (1) | IL238563A0 (es) |
MX (1) | MX2015005548A (es) |
NI (1) | NI201500063A (es) |
PH (1) | PH12015501002A1 (es) |
SG (1) | SG11201503456TA (es) |
WO (1) | WO2014071280A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014248263A1 (en) * | 2013-04-02 | 2015-10-15 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
EP3718569B1 (en) * | 2015-05-22 | 2023-05-03 | Translational Drug Development, LLC | Benzamide and active compound compositions and methods of use |
WO2019051125A1 (en) * | 2017-09-06 | 2019-03-14 | Translational Drug Development, Llc | AMINOBENZIMIDAZOLE DERIVATIVES, TREATMENTS AND METHODS FOR INHIBITING HISTONE DEACETYLASE |
CN105456232A (zh) * | 2015-09-08 | 2016-04-06 | 刘剑 | 一种泊马度胺速溶膜剂及其制备方法 |
CN109071460B (zh) * | 2016-03-02 | 2022-08-09 | 转化药物开发有限责任公司 | 氨基苯并咪唑衍生物 |
WO2018013689A1 (en) * | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof |
CN108721304B (zh) * | 2017-04-17 | 2020-10-16 | 北京大学 | 用于治疗肿瘤的药物组合物及其用途 |
GB202012160D0 (en) * | 2020-08-05 | 2020-09-16 | Vicore Pharma Ab | New compositions |
WO2023158486A2 (en) * | 2022-02-15 | 2023-08-24 | The Broad Institute, Inc. | Cell-type specific targeting contractile injection system |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
JP5339588B2 (ja) * | 2008-11-10 | 2013-11-13 | 国立大学法人 新潟大学 | サリドマイドまたはその誘導体を有効成分とする統合失調症の治療薬 |
JP5553275B2 (ja) * | 2010-03-31 | 2014-07-16 | 国立大学法人金沢大学 | 金属錯体およびこれを有効成分として含有する抗がん剤 |
WO2012145309A1 (en) * | 2011-04-18 | 2012-10-26 | Celgene Corporation | Biomarkers for the treatment of multiple myeloma |
WO2012149299A2 (en) * | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
-
2013
- 2013-11-04 JP JP2015540844A patent/JP2015535291A/ja active Pending
- 2013-11-04 EA EA201590883A patent/EA201590883A1/ru unknown
- 2013-11-04 EP EP13850977.3A patent/EP2914112A4/en not_active Withdrawn
- 2013-11-04 MX MX2015005548A patent/MX2015005548A/es unknown
- 2013-11-04 SG SG11201503456TA patent/SG11201503456TA/en unknown
- 2013-11-04 US US14/440,333 patent/US20150297579A1/en not_active Abandoned
- 2013-11-04 WO PCT/US2013/068237 patent/WO2014071280A1/en active Application Filing
- 2013-11-04 CA CA2889987A patent/CA2889987A1/en not_active Abandoned
- 2013-11-04 BR BR112015010039A patent/BR112015010039A2/pt not_active IP Right Cessation
- 2013-11-04 CN CN201380069405.4A patent/CN104902754A/zh active Pending
- 2013-11-04 AU AU2013337352A patent/AU2013337352A1/en not_active Abandoned
-
2015
- 2015-04-30 IL IL238563A patent/IL238563A0/en unknown
- 2015-05-04 NI NI201500063A patent/NI201500063A/es unknown
- 2015-05-05 PH PH12015501002A patent/PH12015501002A1/en unknown
-
2016
- 2016-03-07 HK HK16102558.2A patent/HK1214552A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20150297579A1 (en) | 2015-10-22 |
AU2013337352A1 (en) | 2015-05-21 |
HK1214552A1 (zh) | 2016-07-29 |
EP2914112A1 (en) | 2015-09-09 |
PH12015501002A1 (en) | 2015-07-27 |
BR112015010039A2 (pt) | 2017-07-11 |
CA2889987A1 (en) | 2014-05-08 |
JP2015535291A (ja) | 2015-12-10 |
CN104902754A (zh) | 2015-09-09 |
EP2914112A4 (en) | 2016-06-15 |
EA201590883A1 (ru) | 2015-09-30 |
IL238563A0 (en) | 2015-06-30 |
WO2014071280A1 (en) | 2014-05-08 |
NI201500063A (es) | 2015-09-10 |
SG11201503456TA (en) | 2015-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501002A1 (en) | Treatment of cancer with pomalidomide in a renally impaired subject | |
EA201491330A1 (ru) | Терапевтически активные соединения и способы их использования | |
PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
MX2021000538A (es) | Uso de sobetirome en el tratamiento de enfermedades de mielinizacion. | |
PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
MX2019008085A (es) | Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros. | |
MX2015013166A (es) | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
MX350312B (es) | Uso terapeutico de la proteina de union a neurotrofina del receptor neutrofico p75. | |
MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
PH12015502112A1 (en) | Cancer treatment using antibodies that bind cell surface grp78 | |
TW201613636A (en) | Methods of treating Alzheimer's Disease | |
EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
PH12015500169A1 (en) | Prediction of treatment response to jak/stat inhibitor | |
MX370953B (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
JP2015535291A5 (es) | ||
WO2014153385A3 (en) | Methods of treating metabolic disorders | |
EA201990403A1 (ru) | Человеческие анти-vegfr-2/kdr-антитела | |
MX2015011905A (es) | Uso de levocetirizina y montelukast en el tratamiento de la vasculitis. | |
IN2012DN02195A (es) | ||
MX2011008994A (es) | Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2. | |
MX2019000677A (es) | Células miméticas de células b. | |
UA84189U (ru) | Способ лечения больных гастроэзофагеальной рефлюксной болезнью на фоне хронического обструктивного заболевания легких | |
TR201819348T4 (tr) | Otizm Bozukluklarının Mentol, Linalool ve/veya İsilin İle Tedavisi ya da Önlenmesi |